Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis

NACompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

November 30, 2010

Conditions
Liver Cancer
Interventions
DEVICE

radiofrequency ablation

Trial Locations (18)

29425

Hollings Cancer Center at Medical University of South Carolina, Charleston

30322

Winship Cancer Institute of Emory University, Atlanta

35294

Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham

48073

William Beaumont Hospital - Royal Oak Campus, Royal Oak

55905

Mayo Clinic Cancer Center, Rochester

76508

Scott and White Cancer Institute, Temple

90048

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles

95817

University of California Davis Cancer Center, Sacramento

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01655

UMASS Memorial Cancer Center - University Campus, Worcester

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

02903

Rhode Island Hospital Comprehensive Cancer Center, Providence

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

78229-3900

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

American College of Radiology Imaging Network

NETWORK

NCT00132041 - Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis | Biotech Hunter | Biotech Hunter